Zidesamtinib demonstrates 93% response rate in ROS1-positive lung cancer

New results from the planetary signifier 1/2 ARROS-1 proceedings showed clinically meaningful enactment with zidesamtinib successful patients with precocious oregon metastatic ROS1-positive non-small compartment lung crab (NSCLC) who had not antecedently received a tyrosine kinase inhibitor (TKI). The findings were presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).